Tyra Biosciences, Inc.
NASDAQ:TYRABiotechnology
-$0.72 today
- Market cap
- $1.35B
- Beta
- 0.75
- P/E (TTM)
- -13.4
- EPS (TTM)
- -$2.12
Volume 0.47M
Average 0.96M
TYRA Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Tyra Biosciences, Inc.NASDAQ: TYRA
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $41.86M rose 31.4% year over year, ahead of the +25.7% change in trailing-twelve-month operating expenses. Sequentially, it rose 14.6% from the prior quarter. Over 3 fiscal years it compounded at +31.1% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +31.4% holds above the trailing-twelve-month pace of +25.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 132.76M USD
- Year-over-year change
- +27.4%
- 4-year CAGR
- +49.9%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 132.76M | +27.4% |
| FY2024 | 2024-12-31 | 104.18M | +30.3% |
| FY2023 | 2023-12-31 | 79.95M | +35.7% |
| FY2022 | 2022-12-31 | 58.93M | +124.2% |
| FY2021 | 2021-12-31 | 26.29M | — |
Operating Expenses vs competitors
How TYRA compares with its peers on the latest reported figures
- TYRA's LTM Mar 2026 operating expenses of $142.77M is the 10th highest of the 11 companies compared; the peer median is $173.79M.
- Its year-over-year change of +25.7% is the 6th highest of 11, against a peer median of +22.6%.
- Over three fiscal years its annual growth of +31.1% compares with a peer median of +30.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $385.56M | +42.1% | +38.4% | 538.2% | |
| LTM Jun 2026 | $297.23M | +30.0% | +30.7% | 174.9% | |
| LTM Mar 2026 | $240.35M | +15.1% | — | — | |
| LTM Mar 2026 | $212.38M | +50.5% | +37.4% | 428.3% | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | $174.06M | +60.0% | +60.5% | — |
| LTM Mar 2026 | $173.51M | -10.6% | -12.1% | 110.5% | |
| LTM Mar 2026 | $168.69M | +127.4% | +30.3% | 780.5% | |
| LTM Mar 2026 | $156.87M | +11.7% | +68.8% | — | |
| LTM Mar 2026 | $149.59M | +2.2% | +15.6% | — | |
| LTM Mar 2026 | $142.77M | +25.7% | +31.1% | — | |
| LTM Mar 2026 | $87.05M | -28.0% | -7.0% | 308.4% | |
| Peer median (excluding TYRA) | $173.79M | +22.6% | +30.7% | 368.4% | |
Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 20.64M | 43.01M | 62.52M | 80.08M | 102.93M |
| Selling, General & Admin | 5.65M | 15.92M | 17.43M | 24.1M | 29.83M |
| Operating Expenses | 26.29M | 58.93M | 79.95M | 104.18M | 132.76M |
| Depreciation & Amortization | 140K | 296K | 357K | 519K | 546K |
| EBITDA | (26.15M) | (55.03M) | (68.78M) | (85.96M) | (119.4M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (26.29M) | (58.93M) | (79.95M) | (104.18M) | (132.76M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 13K | 3.65M | 10.81M | 17.7M | 12.82M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (6K) | 3.6M | 10.81M | 17.7M | 12.82M |
| Income Before Tax | (26.29M) | (55.33M) | (69.13M) | (86.48M) | (119.95M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.29M) | (55.33M) | (69.13M) | (86.48M) | (119.95M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.63) | (1.23) | (1.62) | (1.51) | (2.01) |
| EPS (Diluted) | (0.63) | (1.23) | (1.62) | (1.51) | (2.01) |
| Weighted Avg Shares | 41.44M | 41.88M | 42.7M | 57.22M | 59.6M |
| Weighted Avg Shares (Diluted) | 41.44M | 41.88M | 42.7M | 57.22M | 59.6M |
Tyra Biosciences, Inc.
NASDAQ:TYRA
Intrinsic Alpha fair value
Locked
Current Price
$19.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.